Injective Veyra upgrade vote draws 62% approval: Will INJ extend gains amid strong participation?

Injective Veyra upgrade vote draws 62% approval: Will INJ extend gains amid strong participation?
Injective jumps 10.68% today on Veyra vote

Injective (INJ) is trading at $8.26 after climbing 10.68% intraday. The price remains above its key moving averages, indicating firm buying interest and robust momentum to the upside.

INJ price prediction
24H 0.87%
$6.98
48H -0.72%
$6.87
7D -15.9%
$5.82
1M -0.14%
$6.91
3M -62.72%
$2.58
6M -76.45%
$1.63
12M 31.07%
$9.07
Current price: $6.92 -0.22 3.11%
Real-time Data 20:26
Daily range 6.56 Arrow from to Icon 7.25
Weekly range 6.66 Arrow from to Icon 8.44
Loading...

Highlights

  • Injective is holding a governance vote on the Veyra mainnet upgrade, aiming to add real-world asset infrastructure and enhanced trading protocols.
  • As of November 13, 2026, 62% of votes supported the proposal with 13.97 million INJ staked, though turnout is below the 33.4% quorum.
  • INJ/USD trades at $8.26 after a 10.68% daily jump, with strong upward momentum but overbought signals and an expected range of $7.87 to $8.53.

Governance vote participation and upgrade prospects drive demand

Injective has initiated a governance vote for its major Veyra mainnet upgrade, with the proposal (IIP-717) set to introduce institutional-grade real-world asset infrastructure, enhanced cross-chain interoperability, a request-for-quote trading system, and atomic swaps. As of November 13, 2026, 62% of votes were in favor and approximately 13.97 million INJ had been staked, but total turnout remained below the required 33.4% quorum, according to Kucoin. This wave of community participation and the prospect of substantial technical enhancements appear to be fueling demand for INJ, supporting the asset’s current upside momentum.

Injective asset chart
Injective price dynamics. Source: TradingView.

Overbought momentum as INJ tests strong resistance and support

INJ/USD is above its MA-20 at $7.46, MA-50 at $7.57, and well above the MA-200 at $5.77, while the Ichimoku Kijun sits at $7.48 and offers immediate support. Resistance is seen near $8.53, with support at $7.87 and $7.48. Momentum readings are mixed: RSI is neutral, while both Stochastic RSI and CCI are overbought, highlighting overheating risk. MACD and ADX remain neutral, Bull/Bear Power at 0.28 signals modest buyer strength intraday, and the Awesome Oscillator aligns with the upward movement. Intraday volatility is elevated, with no gap from the previous close, confirming strong upward pressure amid some caution from oscillators.

Consolidation expected as volatility cools after sharp rally

In the short term, INJ is likely to consolidate within the $7.87–$8.53 range as volatility stabilizes following the latest surge. With upside probability very high, a breakout above $8.53 could open the door for further gains. Conversely, a drop below immediate support at $7.48 would indicate risk of a deeper retracement, but this scenario currently appears unlikely barring a shift in participation or sentiment.

Anton Kharitonov, expert at Traders Union, sees solid interest in INJ driven by active community governance over the Veyra mainnet upgrade. He notes that price action remains constructive above key moving averages, but intraday momentum readings suggest caution as overbought signals appear. Political participation has not yet met the required quorum, highlighting some hesitation despite technical enthusiasm. "Until we see stronger turnout on the upgrade vote or a clear breakout above $8.53, I remain cautious on further upside," says Kharitonov.

Earlier, analysts noted that Injective's growth potential hinged on accelerating adoption of its institutional-grade infrastructure and increasing protocol revenue amid an evolving regulatory and competitive landscape. The current initiative to upgrade via the Veyra mainnet vote—coupled with persistent technical strength—adds a significant catalyst, making the upcoming quorum threshold a crucial pivot point for traders monitoring breakout risk above established resistance.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.